Ziopharm Oncology to Present Data from Clinical Studies of Controlled IL-12 in Breast Cancer and Glioblastoma at American Society of Clinical Oncology (ASCO) Annual Meeting

World News: . []



-       Cancer Gene Therapy

BOSTON, May 16, 2018 (GLOBE NEWSWIRE) -- , Inc. (Nasdaq:ZIOP), a biotechnology company focused on development of next generation immunotherapies utilizing gene- and cell-based therapies to treat patients with cancer, today announced that clinical data showing the Company’s Controlled IL-12 platform elicits a sustained increase in killer T cells with a good safety profile in patients with breast cancer and patients with brain cancer has been accepted for presentation at the in Chicago. 

These data were generated from tumor biopsies from two open-label trials that evaluated Ad-RTS-hIL-12 plus veledimex, a gene therapy designed to induce and control expression of the powerful cytokine interleukin 12 (IL-12), in heavily pretreated patients with metastatic breast cancer or recurrent glioblastoma (rGBM).

In addition, the poster presentation will include an update on patient survival data from the Company’s Phase 1 study of Ad-RTS-hIL-12 plus veledimex as monotherapy to treat patients with rGBM. The Company previously reported median overall survival (mOS) of 12.5 months for patients treated with Ad-RTS-hIL-12 plus 20 mg of veledimex (n=15) at a mean follow-up time of 11.1 months as of Oct. 18, 2017. This mOS compares favorably to the 5 to 8 months survival established in historical controls for patients with rGBM. 

“Intratumoral injection of Ad-RTS-hIL-12 plus oral doses of veledimex clearly demonstrate ability to turn cold tumors hot and bring to tumors cancer-fighting T cells that were not there before,” said Francois Lebel. M.D., Ziopharm’s Chief Medical Officer and Executive Vice President for Research & Development. “These data support further development of our Controlled IL-12 platform in combination with immune checkpoint inhibitors, and we have one combination trial initiated in brain cancer and plans to advance a second tumor type later this year.”

Contact: David Connolly Ziopharm Oncology 617-502-1881


More news and information about ZIOPHARM Oncology Inc

Published By:

Globe Newswire: 22:00 GMT Wednesday 16th May 2018

Published: .

Search for other references to "ziopharm" on SPi News

Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2018. [Admin Only]
Sector Publishing Intelligence Ltd.
Ground Floor Offices, Little Keep Gate, Barrack Road, Dorchester, Dorset DT1 1AH
Registered in England and Wales number 0751938.
Privacy Policy | Terms and Conditions | Contact Us

Advertising on SPi News: Information For Advertisers